CMS Proposes Coverage Policy For Transcatheter Edge-to-Edge Mitral Valve Repair
In a new draft National Coverage Determination, the US Medicare agency proposes extending coverage of transcatheter mitral valve repair to certain patients with functional mitral regurgitation.
You may also be interested in...
Abbott’s medical device sales were down about 20% year-over-year in the second quarter of 2020, but diagnostics sales were up 7%. Procedure trends at the end of the second quarter suggest that demand for devices will soon recover to pre-pandemic levels.
Edwards Lifesciences received the CE mark for its PASCAL transcatheter system for treating triscupid valve regurgitation, competing against Abbott’s newly CE-marked TriClip.
Abbott appears well-positioned to weather the pandemic with continued revenue growth in diabetes, heart failure devices and molecular diagnostics.